Vascular Endothelial Growth Factor
Studies from University Medical Center yield new information about vascular endothelial growth factor
Published in Cancer Weekly, February 2nd, 2010
Investigators publish new data in the report 'Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.' According to recent research published in the Journal of Clinical Oncology, "Hypertension is a commonly reported adverse effect after administration of vascular endothelial growth factor (VEGF) inhibitors. Cediranib is a highly potent and selective VEGF signaling inhibitor of all three VEGFRs."
"This study prospectively investigated hypertension management to help minimize dose...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-02-02)
More Articles from Cancer Weekly
- American College of Radiology / American Roentgen Ray Society
Digital mammography delivers significantly less radiation than conventional mammography - American College of Radiology / American Roentgen Ray Society
Ultrasound plus proteomic blood analyses may help physicians diagnose early-stage ovarian cancer - BioMed Central
Friendly bacteria love the humble apple - Institut de recherches cliniques de Montreal
A variant of the gene GFI1 predisposes to a subtype of blood cancer - Journal of the National Cancer Institute
3 esophageal cancer cell lines commonly used in research prove to be from other cancers - Journal of the National Cancer Institute
News brief: Informative method to identify biomarkers for guiding therapy decisions - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
